You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
德琪医药(06996.HK)与Calithera签订全球独家授权协议
阿思达克 05-18 02:52
德琪医药-B(06996.HK)公布,与专注研发治疗肿瘤等危及生命疾病的新型小分子药物的临床阶段生物技术公司-Calithera就Calithera的CD73小分子抑制剂CB-708的开发及商业化订立全球独家授权协议。

根据协议,Calithera将获得一笔首付款及潜在的开发、注册和销售的里程碑付款,总共最多2.55亿美元,并有资格就授权产品的销售获得单位数至低双位数百分点的分级特许权使用费。

CB-708是一款高效、选择性的口服CD73抑制剂,有望在治疗多种肿瘤的单药或联合疗法中释放巨大潜力。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account